Emiplacel - Pluristem

Drug Profile

Emiplacel - Pluristem

Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; PLacental eXpanded cells; PLX PAD; PLX-PAD cell therapy

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pluristem Therapeutics
  • Class Ischaemic heart disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia; Thromboangiitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • Phase III Muscle injury; Peripheral arterial disorders
  • Phase II Intermittent claudication
  • Preclinical Duchenne muscular dystrophy; Graft-versus-host disease
  • No development reported Ischaemic heart disorders; Preeclampsia; Pulmonary arterial hypertension; Tendon injuries

Most Recent Events

  • 10 Oct 2018 Phase-III clinical trials in Muscle injury in USA, Israel (IM)
  • 24 Sep 2018 Phase-III clinical trials in Muscle injury in Germany (IM) (EudraCT2017-005165-49)
  • 08 Aug 2018 Israel’s Ministry of Health approves IND application for emiplacel in Muscle injury and Peripheral arterial disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top